NASDAQ:LYEL

Lyell Immunopharma Stock Earnings Reports

etoro logo Buy LYEL
*Your capital is at risk
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026

Lyell Immunopharma Earnings Calls

Mar 31, 2026
-$1.10 (60.43%)
Release date May 06, 2026
EPS estimate -$2.78
EPS actual -$1.10
EPS Surprise 60.43%
Revenue estimate 3K
Revenue actual 2K
Revenue Surprise -33.33%
Dec 31, 2025
-$7.68 (-257.21%)
Release date Mar 12, 2026
EPS estimate -$2.15
EPS actual -$7.68
EPS Surprise -257.21%
Revenue estimate 15.25K
Revenue actual 6K
Revenue Surprise -60.66%
Sep 30, 2025
-$2.13 (24.20%)
Release date Nov 12, 2025
EPS estimate -$2.81
EPS actual -$2.13
EPS Surprise 24.20%
Revenue estimate -
Revenue actual 15K
Jun 30, 2025
-$2.89 (23.95%)
Release date Aug 12, 2025
EPS estimate -$3.80
EPS actual -$2.89
EPS Surprise 23.95%
Revenue estimate 4K
Revenue actual 8K
Revenue Surprise 100.00%

Last 4 Quarters for Lyell Immunopharma

Below you can see how LYEL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Beat
Release date Aug 12, 2025
Price on release $10.57
EPS estimate -$3.80
EPS actual -$2.89
EPS surprise 23.95%
Date Price
Aug 06, 2025 $11.08
Aug 07, 2025 $11.32
Aug 08, 2025 $10.98
Aug 11, 2025 $10.58
Aug 12, 2025 $10.57
Aug 13, 2025 $10.83
Aug 14, 2025 $10.76
Aug 15, 2025 $10.58
Aug 18, 2025 $10.89
4 days before -4.60%
4 days after 2.98%
On release day 2.46%
Change in period -1.76%
Sep 30, 2025 Beat
Release date Nov 12, 2025
Price on release $17.63
EPS estimate -$2.81
EPS actual -$2.13
EPS surprise 24.20%
Date Price
Nov 06, 2025 $17.88
Nov 07, 2025 $17.51
Nov 10, 2025 $17.68
Nov 11, 2025 $17.25
Nov 12, 2025 $17.63
Nov 13, 2025 $17.41
Nov 14, 2025 $16.93
Nov 17, 2025 $17.42
Nov 18, 2025 $17.93
4 days before -1.40%
4 days after 1.70%
On release day -1.25%
Change in period 0.280%
Dec 31, 2025 Missed
Release date Mar 12, 2026
Price on release $24.78
EPS estimate -$2.15
EPS actual -$7.68
EPS surprise -257.21%
Date Price
Mar 06, 2026 $22.46
Mar 09, 2026 $25.50
Mar 10, 2026 $25.63
Mar 11, 2026 $25.14
Mar 12, 2026 $24.78
Mar 13, 2026 $21.25
Mar 16, 2026 $21.13
Mar 17, 2026 $20.14
Mar 18, 2026 $20.06
4 days before 10.31%
4 days after -19.03%
On release day -14.23%
Change in period -10.69%
Mar 31, 2026 Beat
Release date May 06, 2026
Price on release $20.85
EPS estimate -$2.78
EPS actual -$1.10
EPS surprise 60.43%
Date Price
Apr 30, 2026 $19.73
May 01, 2026 $20.83
May 04, 2026 $20.72
May 05, 2026 $20.62
May 06, 2026 $20.85
May 07, 2026 $20.06
May 08, 2026 $19.33
May 11, 2026 $19.20
May 12, 2026 $19.25
4 days before 5.68%
4 days after -7.67%
On release day -3.79%
Change in period -2.43%

Lyell Immunopharma Earnings History

Earnings Calendar

FAQ

When is the earnings report for LYEL?
Lyell Immunopharma, Inc. (LYEL) has scheduled its earnings report for Aug 11, 2026 after the markets close.

What is the LYEL price-to-earnings (P/E) ratio?
LYEL P/E ratio as of Jun 03, 2026 (TTM) is -1.12.

What is the LYEL EPS forecast?
The forecasted EPS (Earnings Per Share) for Lyell Immunopharma, Inc. (LYEL) for the first fiscal quarter 2026 is -$2.03.

What are Lyell Immunopharma, Inc.'s retained earnings?
On its balance sheet, Lyell Immunopharma, Inc. reported retained earnings of $2.00 thousand for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate ...
GOLDEN STAR
Ticker Change Signal Date
RUN
$12.83
18.86% May 06
GLBE
$31.61
5.35% May 05
SAP
$172.39
10.69% May 05
W
WCLD
$27.34
27.18% Apr 29
ADBE
$243.57
7.61% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE